Reistone Announces First Patient Dosed in Two Phase II Global Studies of SHR0302 JAK Inhibitor for Ulcerative Colitis and Crohn's Disease

SHANGHAI June 14 2019 PRNewswire Reistone Biopharma Company Limited Reistone announced today dosing of the first patient in their Phase II global clinical trials RSJ10101 and RSJ10201 of SHR0302 in patients with Ulcerative Colitis and Crohn's disease resp...